ReviewFrontiers in pharmacology2017
Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy.
Review in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04874935 (The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer
Who cites it
39 citing papers in PubMed, 66 citations in OpenAlex.
- Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.Medical oncology (Northwood, London, England) · 2021Trial
- The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.Medicina (Kaunas, Lithuania) · 2026Article
- Esomeprazole Potentiates the Cytotoxic Effects of Cisplatin in Gastric Carcinoma Cells.Journal of biochemical and molecular toxicology · 2025Article
- Identification of dequalinium as a potent inhibitor of human organic cation transporter 2 by machine learning based QSAR model.Scientific reports · 2025Article
- How Does Cancer Occur? How Should It Be Treated? Treatment from the Perspective of Alkalization Therapy Based on Science-Based Medicine.Biomedicines · 2024Review
- Proton pump inhibitors may increase the risk of cisplatin-induced acute kidney injury in patients with nasopharyngeal carcinoma: a prospective cohort study.Scientific reports · 2024Article
- Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β.Cancer medicine · 2024Article
- Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning.Frontiers in pharmacology · 2024Review
- Long-Term Usage of Proton Pump Inhibitors Associated with Prognosis in Patients with Colorectal Cancer.Cancers · 2023Article
- Influence of proton pump inhibitors on the pathological response of rectal cancer: a multicentre study.Ecancermedicalscience · 2023Article
- Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells.OncoTargets and therapy · 2023Article
- Roles of Human Liver Cytochrome P450 Enzymes in Tenatoprazole Metabolism.Pharmaceutics · 2022Article
- Article
- Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Ameliorating cancer cachexia by inhibiting cancer cell release of Hsp70 and Hsp90 with omeprazole.Journal of cachexia, sarcopenia and muscle · 2022Article
- Nano-Enabled Reposition of Proton Pump Inhibitors for TLR Inhibition: Toward A New Targeted Nanotherapy for Acute Lung Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Proton Pump Inhibitors and Cancer: Current State of Play.Frontiers in pharmacology · 2022Review
- Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity.Frontiers in pharmacology · 2022Article
- Meaning and Significance of "Alkalization Therapy for Cancer".Frontiers in oncology · 2022Article
- Back to basic: Trials and tribulations of alkalizing agents in cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs), H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.